Childhood and Adolescent Central Nervous System Tumours in Spain

Background: Central nervous system (CNS) neoplasms are highly frequent solid tumours in children and adolescents. While some studies have shown a rise in their incidence in Europe, others have not. Survival remains limited. We addressed two questions about these tumours in Spain: (1) Is incidence in...

Descripción completa

Detalles Bibliográficos
Autores: Chirlaque López , María Dolores, Peris-Bonet, Rafael|||0000-0002-4200-2309, Sánchez, Antonia, Cruz, Ofelia|||0000-0001-7102-3283, Marcos-Gragera, Rafael|||0000-0001-9824-3657, Gutiérrez-Ávila, Gonzalo, Quirós García, José Ramón, Almela-Vich, Fernando, López de Munain, Arantza|||0000-0001-6820-9124, Sánchez Pérez, María José|||0000-0003-4817-0757, Franch-Sureda, Paula, Ardanaz, Eva, Galceran, Jaume|||0000-0002-1584-7293, Martos, Carmen, Salmerón, Diego, Gatta, Gemma|||0000-0003-4160-6458, Botta, Laura, Cañete, Adela
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:289530
Acceso en línea:https://ddd.uab.cat/record/289530
https://dx.doi.org/urn:doi:10.3390/cancers15245889
Access Level:acceso abierto
Palabra clave:Childhood CNS tumours
Adolescent CNS tumours
Incidence
Survival
Time trends
Paediatric oncology
Population-based cancer registries
Spain
Descripción
Sumario:Background: Central nervous system (CNS) neoplasms are highly frequent solid tumours in children and adolescents. While some studies have shown a rise in their incidence in Europe, others have not. Survival remains limited. We addressed two questions about these tumours in Spain: (1) Is incidence increasing? and (2) Has survival improved? Methods: This population-based study included 1635 children and 328 adolescents from 11 population-based cancer registries with International Classification of Childhood Cancer Group III tumours, incident in 1983-2007. Age-specific and age-standardised (world population) incidence rates (ASRws) were calculated. Incidence time trends were characterised using annual percent change (APC) obtained with Joinpoint. Cases from 1991 to 2005 (1171) were included in Kaplan-Meier survival analyses, and the results were evaluated with log-rank and log-rank for trend tests. Children's survival was age-standardised using: (1) the age distribution of cases and the corresponding trends assessed with Joinpoint; and (2) European weights for comparison with Europe. Results: ASRw 1983-2007: children: 32.7 cases/10; adolescents: 23.5 cases/10. The overall incidence of all tumours increased across 1983-2007 in children and adolescents. Considering change points, the APCs were: (1) children: 1983-1993, 4.3%^ (1.1; 7.7); 1993-2007, -0.2% (-1.9; 1.6); (2) adolescents: 1983-2004: 2.9%^ (0.9; 4.9); 2004-2007: -7.7% (-40; 41.9). For malignant tumours, the trends were not significant. 5-year survival was 65% (1991-2005), with no significant trends (except for non-malignant tumours). Conclusions: CNS tumour incidence in Spain was found to be similar to that in Europe. Rises in incidence may be mostly attributable to changes in the registration of non-malignant tumours. The overall malignant CNS tumour trend was compatible with reports for Southern Europe. Survival was lower than in Europe, without improvement over time. We provide a baseline for assessing current paediatric oncology achievements and incidence in respect of childhood and adolescent CNS tumours.